Hepatitis Monthly

Published by: Kowsar

The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection

Zahra Heidari 1 , 2 , Bita Moudi 1 , 2 , * , Hamidreza Mahmoudzadeh-Sagheb 1 , 2 and Mohammad Hashemi 3 , 4
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
2 Department of Histology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
3 Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
4 Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
Article information
  • Hepatitis Monthly: March 2016, 16 (3); e34266
  • Published Online: March 4, 2016
  • Article Type: Research Article
  • Received: November 1, 2015
  • Revised: January 31, 2016
  • Accepted: February 8, 2016
  • DOI: 10.5812/hepatmon.34266

To Cite: Heidari Z, Moudi B, Mahmoudzadeh-Sagheb H, Hashemi M. The Correlation Between Interferon Lambda 3 Gene Polymorphisms and Susceptibility to Hepatitis B Virus Infection, Hepat Mon. 2016 ;16(3):e34266. doi: 10.5812/hepatmon.34266.

Copyright: Copyright © 2016, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008; 359(14): 1486-500[DOI][PubMed]
  • 2. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010; 14(1): 1-21[DOI][PubMed]
  • 3. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol. 2000; 15 Suppl-6[PubMed]
  • 4. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2): 97-107[PubMed]
  • 5. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis. 1991; 11(2): 84-92[DOI][PubMed]
  • 6. Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci. 2009; 14(4): 249-58[PubMed]
  • 7. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006; 28: 112-25[DOI][PubMed]
  • 8. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci. 2008; 15(2): 137-45[DOI][PubMed]
  • 9. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst. 2000; 92(14): 1159-64[PubMed]
  • 10. Liu YZ, Hou FQ, Ding P, Ren YY, Li SH, Wang GQ. Pegylated interferon alpha enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients. Virol J. 2012; 9: 274[DOI][PubMed]
  • 11. Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003; 98(1): 144-50[DOI][PubMed]
  • 12. Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol. 2007; 13(12): 1770-87[PubMed]
  • 13. Deng G, Zhou G, Zhai Y, Li S, Li X, Li Y, et al. Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection. Hepatology. 2004; 40(2): 318-26[DOI][PubMed]
  • 14. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003; 22(33): 5093-107[DOI][PubMed]
  • 15. Juran BD, Lazaridis KN. Genomics and complex liver disease: Challenges and opportunities. Hepatology. 2006; 44(6): 1380-90[DOI][PubMed]
  • 16. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401[DOI][PubMed]
  • 17. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4): 1338-45[DOI][PubMed]
  • 18. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol. 2009; 86(1): 23-32[DOI][PubMed]
  • 19. Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV. Regulation of apoptosis by type III interferons. Cell Prolif. 2008; 41(6): 960-79[DOI][PubMed]
  • 20. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, et al. IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol. 2007; 178(8): 5086-98[PubMed]
  • 21. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, et al. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther. 2008; 7(7): 1109-15[PubMed]
  • 22. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011; 54(4): 716-22[DOI][PubMed]
  • 23. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005; 79(6): 3851-4[DOI][PubMed]
  • 24. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol. 2008; 121(5): 1108-11[DOI][PubMed]
  • 25. Uze G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie. 2007; 89(6-7): 729-34[DOI][PubMed]
  • 26. Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 2010; 21(4): 237-51[DOI][PubMed]
  • 27. Li MC, Wang HY, Wang HY, Li T, He SH. Liposome-mediated IL-28 and IL-29 expression in A549 cells and anti-viral effect of IL-28 and IL-29 on WISH cells. Acta Pharmacol Sin. 2006; 27(4): 453-9[DOI][PubMed]
  • 28. Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int. 2011; 31(8): 1118-26[DOI][PubMed]
  • 29. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265): 798-801[DOI][PubMed]
  • 30. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006; 80(9): 4501-9[DOI][PubMed]
  • 31. Hashemi M, Moazeni-Roodi A, Bahari A, Taheri M. A tetra-primer amplification refractory mutation system-polymerase chain reaction for the detection of rs8099917 IL28B genotype. Nucleosides Nucleotides Nucleic Acids. 2012; 31(1): 55-60[DOI][PubMed]
  • 32. Zhu H, Butera M, Nelson DR, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J. 2005; 2: 80[DOI][PubMed]
  • 33. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis. 2010; 202(11): 1749-53[DOI][PubMed]
  • 34. Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther. 2011; 16(5): 629-37[DOI][PubMed]
  • 35. Chen J, Wang L, Li Y, Cai B, Fu Y, Liao Y, et al. Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese. PLoS One. 2012; 7(12)[DOI][PubMed]
  • 36. Lampertico P, Vigano M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology. 2013; 57(3): 890-6[DOI][PubMed]
  • 37. Peng LJ, Guo JS, Zhang Z, Shi H, Wang J, Wang JY. IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens. 2012; 79(4): 302-5[DOI][PubMed]
  • 38. Martin-Carbonero L, Rallon NI, Benito JM, Poveda E, Gonzalez-Lahoz J, Soriano V. Short communication: Does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B? AIDS Res Hum Retroviruses. 2012; 28(10): 1262-4[DOI][PubMed]
  • 39. Conde SR, Rocha LL, Ferreira VM, Monteiro JC, Filgueiras NK, Lins PA, et al. Absence of correlation between IL-28B gene polymorphisms and the clinical presentation of chronic hepatitis B in an Amazon Brazilian population. Dis Markers. 2014; 2014: 534534[DOI][PubMed]
  • 40. Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, et al. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha. J Gastroenterol Hepatol. 2013; 28(5): 861-6[DOI][PubMed]
  • 41. Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology. 2012; 142(3): 513-520 e1[DOI][PubMed]
  • 42. Wu X, Xin Z, Zhu X, Pan L, Li Z, Li H, et al. Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral Res. 2012; 93(2): 297-300[DOI][PubMed]
  • 43. Lee DH, Cho Y, Seo JY, Kwon JH, Cho EJ, Jang ES, et al. Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence. Intervirology. 2013; 56(2): 84-90[DOI][PubMed]
  • 44. Ren S, Lu J, Du X, Huang Y, Ma L, Huo H, et al. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother. 2012; 61(9): 1433-9[DOI][PubMed]
  • 45. Li Y, Shi Y, Chen J, Cai B, Ying B, Wang L. Association of polymorphisms in interleukin-18 and interleukin-28B with hepatitis B recurrence after liver transplantation in Chinese Han population. Int J Immunogenet. 2012; 39(4): 346-52[DOI][PubMed]
  • 46. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10): 1105-9[DOI][PubMed]
  • 47. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013; 45(2): 164-71[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader